Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of AT2101 in treatment-naive adults with type 1 Gaucher disease
2007-003359-35Phase 2Completed
- Sponsor
- Amicus Therapeutics
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Afegostat in Gaucher disease type 1 (GD1) (2 arms), sponsored by Amicus Therapeutics. Primary endpoint: Safety and tolerability (physical examination). Started Sep 2007; status: completed.
02
Drugs
Afegostat
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on 2007-003359-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003359-35.